GlassScriptPhysician profile
Sumalee Z Ryan
NPI 1336625441
$6,411.26
in general payments reported to CMS, 2019-2025
31 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $1,353 · 2023: $1,166 · 2024: $2,160 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394 · Travel and Lodging: $2,246 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.47 |
| Travel and Lodging | $2,246.20 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,457.45 | 2024-2025 | |
| Novo Nordisk INC | $1,229.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Beta Bionics, INC. | $340.45 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $275.27 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $260.27 | 2022-2024 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Nevro Corp. | $232.73 | 2021-2024 | Senza |
| Insulet Corporation | $219.74 | 2022-2024 | Omnipod |
| Lilly USA, LLC | $149.11 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $148.48 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.17 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $128.67 | 2021-2023 | Steglatro, Steglujan, Segluromet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.53 | 2022-2024 | Jardiance |
| Amgen INC. | $88.14 | 2022-2024 | Evenity, Prolia |
| Tandem Diabetes Care, INC. | $70.93 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $69.37 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $64.80 | 2024 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $52.51 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $44.77 | 2022-2024 | Unithroid |
| Ascensia Diabetes Care US INC. | $39.43 | 2023-2024 | |
| Grt US Holding, INC. | $36.70 | 2022 | |
| Biocomposites INC | $33.57 | 2025 | Stimulan |
| Horizon Therapeutics Plc | $26.94 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.71 | 2022 | |
| Eisai INC. | $24.18 | 2023 | |
| Eusa Pharma (US) LLC | $23.68 | 2022 | |
| Recordati_rare_diseases_inc. | $23.68 | 2022 | |
| Corcept Therapeutics | $23.00 | 2022 | |
| Blueprint Medicines Corporation | $21.78 | 2021 | |
| Esperion Therapeutics, INC. | $20.04 | 2024 | Nexletol |
| Ibsa Pharma INC. | $14.78 | 2024 | Licart, Tirosint |
| Tolmar Pharmaceuticals, INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumalee Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.